Amarin Corp Plcuk (AMRN) Receivables (2013 - 2026)
Amarin Corp Plcuk (AMRN) reported Receivables of $123.0 million for Q1 2026, up 15.31% year-over-year from $106.7 million in Q1 2025, and down 15.14% quarter-over-quarter from $145.0 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Receivables (2013 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 14 years of Receivables data on file, last reported at $123.0 million in Q1 2026.
- Receivables for Q1 2026 came in at $123.0 million, up 15.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $123.0 million (up 15.31% YoY), and the FY2025 annual result was $145.0 million, up 8.95% from the prior year.
- Receivables fell to $123.0 million in Q1 2026 per AMRN's latest filing, from $145.0 million in the prior quarter.
- Over five years, Receivables peaked at $189.8 million in Q2 2022 and troughed at $106.7 million in Q1 2025.
- A 5-year average of $134.8 million and a median of $131.0 million in 2022 frame the typical range for Receivables.
- The sharpest annual moves came in 2022 and 2023: Receivables declined 27.15% in 2022, then climbed 22.67% in 2023.
- A 5-year view of Receivables shows it stood at $131.0 million in 2022, then rose by 22.67% to $160.7 million in 2023, then fell by 17.19% to $133.1 million in 2024, then grew by 8.95% to $145.0 million in 2025, then dropped by 15.14% to $123.0 million in 2026.
- Business Quant data shows AMRN's Receivables at $123.0 million in Q1 2026, $145.0 million in Q4 2025, and $127.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 10.46 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 21.18 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 17.72 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 12.48 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 12.21 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 9.14 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 5.33 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 12.59 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 9.52 Bn |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn | 123.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 123.04 Mn |
| Dec 31, 2025 | 144.98 Mn |
| Sep 30, 2025 | 127.31 Mn |
| Jun 30, 2025 | 134.10 Mn |
| Mar 31, 2025 | 106.70 Mn |
| Dec 31, 2024 | 133.07 Mn |
| Sep 30, 2024 | 130.25 Mn |
| Jun 30, 2024 | 150.63 Mn |
| Mar 31, 2024 | 115.81 Mn |
| Dec 31, 2023 | 160.69 Mn |
| Sep 30, 2023 | 122.40 Mn |
| Jun 30, 2023 | 155.10 Mn |
| Mar 31, 2023 | 133.24 Mn |
| Dec 31, 2022 | 130.99 Mn |
| Sep 30, 2022 | 123.38 Mn |
| Jun 30, 2022 | 189.78 Mn |
| Mar 31, 2022 | 110.20 Mn |
| Dec 31, 2021 | 163.65 Mn |
| Sep 30, 2021 | 149.40 Mn |
| Jun 30, 2021 | 182.26 Mn |